The FDA drug approval process is known to be a lengthy and rigorous one. But the FDA-approved ingredient phenylephrine — found in common cold medicines like Sudafed, Mucinex, and NyQuil — was recently found to be no better than a placebo. Phenylephrine has been on store shelves for nearly 90 years. How could that happen?

In this episode of Tiny Matters, Sam and Deboki are joined by none other than Deboki's dad, Deb Chakravarti. Deb is a professor with years of industry experience and the current director of the York College FDA Partnership. He helps dissect the FDA's recent findings and how its history and ever-evolving role in the pharmaceutical industry contributed to phenylephrine being used in oral cold medicines for so long.

Deb, Deboki and Sam also unpack pharmaceutical ethics cases, like thalidomide in the 1950s and 60s, and the case of Vioxx in the early 2000s, which led to tens of thousands of deaths.

Sam and Deboki cap off the episode with tiny show and tells about how the nose is really 2 noses (!) and the story of a new, ingestible, vitamin-sized capsule that could protect people from dying of an opioid overdose, sleep apnea, or other conditions that depress breathing.

Check out PNAS Science Sessions here and wherever you listen to podcasts. 

Links to the Tiny Show & Tell stories are here and here. Pick up a Tiny Matters mug here! All Tiny Matters transcripts are available here.